Abstract: Provided herein are, inter alia, humanized 1E9 antibodies capable of binding CD73. The humanized antibodies are useful for the treatment of cancer. Further provided are nucleic acids encoding humanized 1E9 antibodies and methods of inhibiting cell proliferation using the humanized antibodies provided herein.

Abstract: Provided are compositions for use in methods for treating diseases associated with expression of mesothelin comprising administering a cell that expresses a chimeric antigen receptor (CAR) specific to mesothelin in combination with a PD-L1 inhibitor.

Abstract: Combination therapies comprising antibody molecules that specifically bind to LAG-3 are disclosed. The combination therapies can be used to treat, prevent and/or diagnose cancerous or infectious disorders.

Abstract: Combination therapies comprising antibody molecules that specifically bind to PD-1 disclosed. The combination therapies can be used to treat or prevent cancerous or infectious conditions and disorders.

Abstract: Antibody molecules that specifically bind to PD-L1 are disclosed. Combination therapies comprising the anti-PD-L1 antibody molecules are also disclosed. The anti-PD-L1 antibody molecules can be used to treat, prevent and/or diagnose cancerous or infectious conditions and disorders.

Abstract: Antibody molecules that specifically bind to PD-1 are disclosed. The anti-PD-1 antibody molecules can be used to treat, prevent and/or diagnose cancerous or infectious conditions and disorders.

Abstract: Antibody molecules that specifically bind to PD-L1 are disclosed. Combination therapies comprising the anti-PD-L1 antibody molecules are also disclosed. The anti-PD-L1 antibody molecules can be used to treat, prevent and/or diagnose cancerous or infectious conditions and disorders.

Abstract: Antibody molecules that specifically bind to LAG-3 are disclosed. The anti-LAG-3 antibody molecules can be used to treat, prevent and/or diagnose cancerous or infectious disorders.

Abstract: Antibody molecules that specifically bind to LAG-3 are disclosed. The anti-LAG-3 antibody molecules can be used to treat, prevent and/or diagnose cancerous or infectious disorders.

Abstract: Antibody molecules that specifically bind to PD-1 are disclosed. The anti-PD-1 antibody molecules can be used to treat, prevent and/or diagnose cancerous or infectious conditions and disorders.

Abstract: Herbicidal oil dispersions comprising (a) desmedipham and/or phenmedipham, ethofumesate and lenacil, (b) one or more surfactants, c) one or more compounds which as far as possible are polar but at the same time are water-insoluble or have a solubility in water of up to 5 g/l, from the group of fully esterified organic phosphates and fully esterified phosphonates, as solvents, d) optionally further organic solvents, e) optionally further, customary formulating auxiliaries, f) optionally water are stable formulations and are suitable for controlling weeds, particularly for selective control in beet crops.

Abstract: Herbicidal oil dispersions comprising (a) desmedipham and/or phenmedipham, ethofumesate and lenacil, (b) one or more surfactants, c) one or more compounds which as far as possible are polar but at the same time are water-insoluble or have a solubility in water of up to 5 g/l, from the group of fully esterified organic phosphates and fully esterified phosphonates, as solvents, d) optionally further organic solvents, e) optionally further, customary formulating auxiliaries, f) optionally water are stable formulations and are suitable for controlling weeds, particularly for selective control in beet crops.

Abstract: Antibody molecules that specifically bind to PD-1 are disclosed. The anti-PD-1 antibody molecules can be used to treat, prevent and/or diagnose cancerous or infectious conditions and disorders.

Abstract: Antibody molecules that specifically bind to LAG-3 are disclosed. The anti-LAG-3 antibody molecules can be used to treat, prevent and/or diagnose cancerous or infectious disorders.

Abstract: The present invention relates to the use of the ALS inhibitor herbicides for controlling unwanted vegetation in ALS inhibitor herbicide tolerant Beta vulgaris plants, more especially, present invention relates to the use of ALS inhibitor herbicides for control of unwanted vegetation in Beta vulgaris, preferably in sugar beet growing areas in which the Beta vulgaris, preferably sugar beet comprise mutations in the ALS gene where the tryptophan at position 569 in the encoded ALS enzyme is substituted by another amino acid (preferably by leucine), and a mutation in the ALS gene where the proline at position 188 in the encoded ALS enzyme is substituted by another amino acid (preferably by serine).

Abstract: Antibody molecules that specifically bind to PD-1 are disclosed. The anti-PD-1 antibody molecules can be used to treat, prevent and/or diagnose cancerous or infectious conditions and disorders.

Abstract: The present invention relates to an ALS inhibitor herbicide tolerant crop plants, such as allotetraploid Brassica plants, such as B. napus plants, progeny and parts thereof comprising mutations in acetolactase genes.

Abstract: The present invention relates to an ALS inhibitor herbicide tolerant polyploid plants, such as B. napus or B. juncea plants, progeny and parts thereof comprising mutations in all acetolactase genes.

Abstract: The present invention relates to the use of the ALS inhibitor herbicides for controlling unwanted vegetation in ALS inhibitor herbicide tolerant Brassica plants, more especially, the present invention relates to the use of ALS inhibitor herbicides for control of unwanted vegetation in Brassica growing areas which Brassica plants comprise non-transgenic mutations of their endogenous acetolactate synthase (ALS) genes I and III.

Abstract: The present invention relates to an ALS inhibitor herbicide tolerant polyploid plants, such as B. napus or B. juncea plants, progeny and parts thereof comprising a mutation of all acetolactase genes.